Rosuvastatin Efficacy and Safety Evaluation in Hypercholesterolaemic Patients

A Multi-centre, Open Label, Non-randomised, Non Interventional, 24 Weeks Study for the Efficacy and Safety of Rosuvastatin Following Its Administration in Real Life Clinical Practice in Greek Hypercholesterolaemic Patients

This is a single-arm, phase IV, open-label, prospective, non interventional study to evaluate the efficacy, tolerability and safety of rosuvastatin administered for 24 weeks in approximately 900 Greek subjects with hypercholesterolemia under normal clinical practice.

Inclusion Criteria:

• Patients with hypercholesterolaemia who are already in treatment with rosuvastatin according to the approved SPC for no longer than 1 month prior to study entry
• Patients that are able to read, understand and sign the Patient Information & Consent Form
• Patients that are willing to comply with all study requirements

Exclusion Criteria:

• Patients that are likely not to comply with all study requirements
• Patients that currently participate or have participated in a 3 months period prior to study entry in another clinical trial
• Female of child bearing potential that do not use a reliable method of contraception. Pregnancy or lactation.
• Patients that meet any of the contraindications described in the approved SPC